Evans syndrome (ES) is a rare autoimmune disorder, which is defined by a combination of direct Coombs test positive hemolytic anemia and immune thrombocytopenia.^[@R1]^ Although most cases have no obvious underlying etiology, rare monogenic forms have been identified in the last years.^[@R2]^ ES can affect different organs, manifesting with hepatomegaly, splenomegaly,^[@R3][@R4][@R5]^ and lymphocytic infiltration of nonlymphoid organs, including the brain.^[@R6],[@R7]^ A case report from 2013 described a patient who had ES in addition to a sterile brain inflammation, which, from a clinical perspective, was indistinguishable from MS.^[@R8]^

Recessive loss-of-function (LoF) mutations in the tripeptidyl peptidase II (*TPP2*) gene were found to cause a specific form of ES in patients, manifesting with neurodevelopmental delay and impaired glycolysis.^[@R9],[@R10]^ *TPP2* is a cytosolic protease; its main activity is the removal of tripeptides from the N-terminus of longer peptides, to generate free amino acids for protein synthesis and energy production.^[@R11]^ This *TPP2*-linked phenotype was proposed to be designated as "TPP2-related immunodeficiency, autoimmunity and neurodevelopmental delay with impaired glycolysis and lysosomal expansion" (TRIANGLE) disease.^[@R9]^ Here, we report on a family with 3 affected siblings initially diagnosed with a mild and nonprogressive form of MS. We identified a homozygous missense mutation in *TPP2* as a likely cause for the disease in this family.

Methods {#s1}
=======

Study participants {#s1-1}
------------------

We clinically evaluated a consanguineous family from Syria with 3 siblings diagnosed with MS and a suggestive pattern of autosomal recessive inheritance. In brief, the disease course observed in the siblings is consistent with a benign relapsing-remitting MS even 27 (II.1) and 24 (II.2) years after the onset of clinical symptoms. The female sibling (II.3) had a single neurologic episode of demyelination and no further clinical relapses over the following 14 years. The Expanded Disability Status Scale was not more than 1.5 in any of the siblings. All of them reported to have had frequent infections of the upper respiratory tract during their childhood and adulthood. All 3 siblings showed low but normal lymphocyte count between 1 and 1.3 × 10^3^/μL (normal range is between 1.0 and 4 × 10^3^/μL) as tested several times between 2008 and 2017. However, they have never experienced other clinical signs typical for ES, such as thrombocytopenia or hemolytic anemia. A detailed clinical description in form of a timetable and magnetic resonance tomography images are provided in figure e-1 ([links.lww.com/NXG/A108](http://links.lww.com/NXG/A108)), figure e-2 ([links.lww.com/NXG/A109](http://links.lww.com/NXG/A109); legends [links.lww.com/NXG/A130](http://links.lww.com/NXG/A130)), and in the supplementary information ([links.lww.com/NXG/A110](http://links.lww.com/NXG/A110)).

For the targeted sequence analysis, we ascertained 382 MS patients from Europe (Austria and Germany) and 183 MS cases from Jordan. In addition, we surveyed exome data from 261 MS patients from Canada for mutations in the *TPP2* gene, which were collected through the longitudinal Canadian Collaborative Project on the Genetic Susceptibility to MS^[@R12]^ ([table 1](#T1){ref-type="table"}). All patients were diagnosed with MS according to published criteria.^[@R13][@R14][@R15]^

###### 

Additional MS cases and controls for targeted sequence and genotyping analysis

![](NG2018007732TT1)

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

Written informed consent was obtained from all study participants; the study was approved by the local ethics committee (EK.535/2004/20179 for the neuropathologic part and EK Nr:2195/2016 for MS patients).

Homozygosity mapping and exome sequencing {#s1-3}
-----------------------------------------

Homozygous regions shared between all 3 siblings were mapped using Affymetrix GenomeWideSNP 6 data from the affected siblings and their healthy parents with the online Homozygosity Mapper tool ([homozygositymapper.org](http://www.homozygositymapper.org)).

Whole exome data were generated from individuals II.1 and II.2. Exomes were enriched with SureSelect Human All Exon 50 Mb kit (AgilentTechnologies, Santa Clara, CA). Sequencing of postenrichment libraries was carried out on the Illumina HiSeq 2000 sequencing instrument (Illumina, San Diego, CA) as 2 × 100 bp paired-end runs. Variants were filtered for homozygosity and a minor allele frequency (MAF) smaller than 2% in our in-house data set of approximately 10,000 control exomes from patients with other unrelated diseases and exomes and in public available databases (exome aggregation consoritum \[ExAC\] database and 1000 Genomes).

Exome sequencing of the Canadian patients was done on an Ion Proton sequencer (Life Technologies, Carlsbad, CA). Exome data were analyzed as previously described.^[@R16]^

Targeted capture sequencing, single-nucleotide polymorphism genotyping, and in silico prediction {#s1-4}
------------------------------------------------------------------------------------------------

Illumina TruSeq Custom Amplicon Kit was used to target all exonic and flanking intronic regions of *TPP2* and excision repair cross-complementation group 5 (*ERCC5*) in 382 European and 183 Jordanian MS patients. Fast-QC files were subsequently analyzed with an in-house pipeline. All identified variants were subsequently validated with Sanger sequencing. Homozygous variants in *TPP2* (p.Cys28Gly, p.Thr676Ile) and *ERCC5* (p.S1078A) were genotyped with custom TaqMan single-nucleotide polymorphism genotyping assays.

TPP2 protein expression in MS and control brain tissue {#s1-5}
------------------------------------------------------

Expression of TPP2 was assessed in formaldehyde-fixed and paraffin-embedded autopsy tissues from 13 MS patients and 16 controls archived at the Center for Brain Research of the Medical University of Vienna (detailed clinical characteristics in supplementary information, [links.lww.com/NXG/A110](http://links.lww.com/NXG/A110)). Expression of TPP2 was analyzed in the normal-appearing white matter (NAWM); initial, early active, late active, and inactive lesion sites in the white matter of MS patients; and in the normal white matter of controls. Lesion stages were defined as described in detail before.^[@R17]^

TPP2 RNA Western blot analysis {#s1-6}
------------------------------

Using a TaqMan gene expression assay, *TPP2* whole blood mRNA expression was quantitatively assessed for all individuals of the index family, 7 randomly chosen individuals affected with MS and 3 healthy controls (GAPDH, Hs03929097_g1). Immunoblotting was performed with peripheral blood mononuclear cell (PBMC) lysates from the index patient (II.1), his affected brother (II.2), and 3 control individuals. Primary antibodies for TPP2 (1:500, 14981S; Cell Signaling) and endogenous control beta-actin were used.

TPP2 enzymatic activity {#s1-7}
-----------------------

Blood samples from index patient II.1 and 2 healthy controls were prepared according to the partial lysis method ([wch.sa.gov.au/services/az/divisions/labs/geneticmed/nrl_methods.html](http://www.wch.sa.gov.au/services/az/divisions/labs/geneticmed/nrl_methods.html)). Enzymatic activity was measured as described previously.^[@R18]^

Results {#s2}
=======

Identification of a homozygous mutation in the *TPP2* gene as a likely cause for a sterile brain inflammation in a consanguineous Syrian family {#s2-1}
-----------------------------------------------------------------------------------------------------------------------------------------------

To identify the responsible gene of a benign brain inflammation, mimicking a nonprogressive form of MS, in a consanguineous family with 3 affected siblings, we performed homozygosity mapping and whole exome sequencing. After filtering variants for allele frequency (MAF \< 2%) and homozygosity, only 2 novel autosomal homozygous missense variants were left to be shared by all siblings. We identified a c.82T\>G, p.Cys28Gly variation in the *TPP2* gene, a serine peptidase that removes tripeptides from the N-terminus of longer peptides and a c.3232T\>G, p.Ser1078Ala variation in the *ERCC5* gene, known to be involved in DNA repair. These 2 variants were confirmed in heterozygous state in the healthy parents. None of the 2 variants is present in any publicly available databases. The 2 genes are in close vicinity, located on chromosome 13q33.1 and map to the only homozygous region shared by all 3 affected siblings ([figure 1, A--C](#F1){ref-type="fig"}).

![Mutation identification and Western blot\
(A) Exome sequencing alignment data of the homozygous *TPP2* mutation in II.1 and II.2 visualized with the IGV tool. (B) Pedigree of consanguineous Syrian family (MS01) affected with MS. Sanger chromatograms of heterozygous parents and homozygous siblings are depicted below their respective symbol. Arrow, position of mutation. (C) Homozygosity plot from Syrian family. Red bars, regions of homozygosity; arrow, homozygous block shared by all 3 siblings containing TPP2 and ERCC5. (D) Chromatograms of homozygous and heterozygous p. Thr676Ile *TPP2* mutation carrier of confirmatory sequencing cohort. (E) Western blot of *TPP2* in PBMCs from II.1, II.2, and 3 healthy control individuals. Black filled symbols = affected; ERCC5 = excision repair cross-complementation group 5; IGV = integrated genome viewer; mt/mt = homozygous for the mutation; open symbols = unaffected; PBMC = peripheral blood mononuclear cell; TPP2 = tripeptidyl peptidase II; wt/mt = heterozygous for the mutation.](NG2018007732FF1){#F1}

Identification of a second rare homozygous variant in the *TPP2* gene in a Jordanian MS patient {#s2-2}
-----------------------------------------------------------------------------------------------

As the phenotype of the family was almost indistinguishable from a benign form of MS, we wondered whether other patients diagnosed with MS might carry biallelic variants in either of the 2 genes. Sequencing of both genes in additional 382 unrelated MS cases from Europe and 183 MS patients from Jordan identified one further homozygous variation in *TPP2* (c.2027C\>G, p.Thr676Ile, rs760347832), in a Jordanian patient ([table 2](#T2){ref-type="table"}). This variant was also present in heterozygous state in 2 additional MS patients from Jordan ([figure 1D](#F1){ref-type="fig"}, clinical details in supplementary information, [links.lww.com/NXG/A110](http://links.lww.com/NXG/A110)). We did not find any rare homozygous or compound heterozygous variants in the *ERCC5* gene in the additionally sequenced MS cases. Inspection of the ExAC database reveals *TPP2* as highly constraint (missense: *Z* score = 3.07, LoF: pLI = 1.00) and less tolerant to variation than *ERCC5* (missense: *Z* score −0.61, pLI = 0.00). In fact, considering the evidence for both genes, *TPP2* appeared to be the stronger candidate because of the greater inherent biological plausibility.

###### 

Missense variants identified in the index family and follow-up cases

![](NG2018007732TT2)

In total, we identified 4 novel or known rare missense variants (MAF \< 2%) in *TPP2*. Apart from p.Thr676Ile, all other variations (p.Ile551Val, p.Glu1012Gly, p.Gln1141Pro) occurred in heterozygous form ([table 2](#T2){ref-type="table"}). We further assessed exome data of 261 MS cases from Canada but did not identify any rare homozygous or compound heterozygous variants in either gene. Subsequently, we genotyped all 3 homozygous variations (*TPP2*: p.Gly28Cys, p.Thr676Ile and *ERCC5*: p.S1078A) in an additional cohort of 233 Jordanian MS cases and 452 ethnically matched Jordanian controls and identified one further Jordanian MS patient carrying the *TPP2*-p.Thr676Ile variant in heterozygous state. Of note, the variant was not found in any of the 452 Jordanian controls. However, *TPP2*-p.Thr676Ile is present in heterozygous form in 6 individuals in the ExAC database. Although, there is no definite evidence for *TPP2* as a putative high-penetrant variant in other MS patients, the *TPP2*-Thr676Ile is an interesting candidate variant, worth to be followed up in more probands.

TPP2 protein levels are reduced in patients of the Syrian MS family {#s2-3}
-------------------------------------------------------------------

Next, we investigated whether *TPP2* mRNA and protein levels differed in patients and controls. Whole blood mRNA levels did not show any difference between *TPP2* homozygous mutation carriers, heterozygous parents, and controls (data not shown). However, Western blot analysis showed a marked reduction in TPP2 protein amount in PBMCs from the 2 affected brothers, when compared with sex- and age-matched control individuals ([figure 1, E](#F1){ref-type="fig"}). Unfortunately, no blood was available from the affected sister for further analysis.

To assess a possible effect of the mutation on TPP2 enzymatic activity, we used lysates from erythrocytes and leukocytes from patient II.1 and 2 healthy control individuals. The activity in erythrocytes from 3 samples per person was 0·42 ± 0·10 and 0·50 ± 0·15 nmol·min·^−1^·mg^−1^ protein for the patient and the controls, respectively. In leukocyte lysates, the activity was 8·8 ± 1·3 and 7·1 ± 1·1 nmol·min·^−1^·mg^−1^ for the patient and the controls, respectively. The measured activity is inhibited to \>95% with the specific TPP2 inhibitor butabindide,^[@R19]^ thus demonstrating that the activity is indeed dependent on TPP2 and not because of a contaminating or compensatory activity. TPP2 in lysates from erythrocytes from both, the patient and the controls, form the normal size complex, as determined by size exclusion chromatography (data not shown). In conclusion, these data show that, although the mutation goes along with reduced protein levels, no significant reduction in enzyme activity is observed in the patients at least in peripheral blood erythrocytes and leukocytes.

TPP2 protein and mRNA levels are increased at sites of active inflammatory demyelination {#s2-4}
----------------------------------------------------------------------------------------

To find out whether *TPP2* also plays a role in MS disease process in nonmutation carriers, we performed immunohistochemistry analysis in brain autopsy samples of 13 MS patients and 16 controls. We found a constitutive expression of TPP2 in neurons and astrocytes. Expression in these cells was similar between controls and MS patients. However, we found a highly selective expression of TPP2 in microglia within and around active MS lesions. While expression was sparse or absent in the NAWM of MS and control brain tissue, increased expression was seen in the periplaque white matter ([figure 2, A--C](#F2){ref-type="fig"}). In particular, microglia nodules, which are abundant in this area close to active lesions, showed pronounced staining. The highest expression of TPP2 was seen in initial stages of MS lesions, characterized by profound microglia activation, oligodendrocyte apoptosis, and initial myelin damage. In the demyelinated portion of the lesions, the expression of TPP2 in microglia decreased from the lesion edge toward the lesion center and was largely absent in microglia in the inactive lesion center. The pattern of microglia TPP2 expression was similar in classic active lesions seen in acute and relapsing MS and in slowly expanding lesions, which are the dominant active lesions in progressive MS. Double staining confirmed that TPP2 expression was present in macrophages/microglia, expressing the phagocytosis-associated marker CD68 and major histocompatibility complex (MHC) Class I and Class II molecules ([figure 2, B](#F2){ref-type="fig"}). In addition, some lymphocytes in perivascular inflammatory infiltrates also expressed TPP2.

![TPP2 expressions in MS\
(A) No expression in NAWM, while increased expression was seen in the PPWM with staining of some microglia nodules. The highest expression of TPP2 was seen in initial stages (Initial) of MS lesions, where most of the activated microglia expressed TPP2. TPP2 expression decreased from the lesion edge toward the lesion center. (B) Double staining confirmed that TPP2 expression was present in macrophages/microglia, expressing the phagocytosis-associated marker CD68 and MHC Class I and Class II molecules. (C) Quantification of TPP2-positive cell counts. Box plots displaying the number of microglia per mm^2^ in regions of interest. Significantly more TPP2 expression was found in MS NAWM, inactive MS lesions, PPWM, initial lesions and in EA or LA lesions of MS patients compared with control white matter. \*\*\**p* \< 0·001, \*\**p* \< 0·01, Wilcoxon test and Mann-Whitney *U* test. (D) *TPP2* mRNA expression in brain lesions of MS patients and controls. Figure is derived from the data set GDS4218 deposited in the GEO Profile database. EA = early active; GEO Profile = gene expression omnibus profile; LA = late active; MHC = major histocompatibility complex; NAWM = normal-appearing white matter; PPWM = periplaque white matter; TPP2 = tripeptidyl peptidase II.](NG2018007732FF2){#F2}

In addition, we surveyed the gene expression omnibus profile (GEO Profile) database for *TPP2* expression linked to MS. In line with our experiment, a microarray analysis performed in brain samples of MS patients revealed a significant upregulation of *TPP2* mRNA in MS brain lesions compared with control individuals ([figure 2, D](#F2){ref-type="fig"}).^[@R20]^

Discussion {#s3}
==========

Our study shows the identification of a causative mutation in a consanguineous family with a suggestive recessive inheritance pattern presenting with a sterile brain inflammation, mimicking MS. The family members presented clinically characteristic attacks of MS and typical MRI lesions fulfilling diagnostic criteria for MS. Two siblings were positive for oligoclonal bands in their CSF. However, the exceptionally benign disease course, with almost no progression in over 20 years, even in the absence of any therapy in one of the siblings let us doubt on the diagnosis of typical MS.

In line with our anticipated inheritance pattern, we identified the homozygous missense mutation (p.Cys28Gly) in the *TPP2* gene in all 3 siblings. Homozygosity mapping and exome sequence filtering identified the genomic location around *TPP2* and *ERCC5* as the only region within in the entire genome shared by all 3 affected siblings. Moreover, the *TPP2* p.Cys28Gly mutation is absent in all publicly available databases (including \>60,000 individuals from the ExAC database and 10,000 in house controls). *TPP2* LoF mutations were found in patients with ES; those patients present among other severe symptoms, respiratory tract infections.^[@R9]^ Notably, all 3 siblings suffered from frequent upper respiratory tract infections in their childhood and adulthood. In addition, they all showed marginally low lymphocytic counts. We think, this possibly reflects subthreshold signs for ES and supports that the *TPP2* variant is phenotypically effective.

As we assume recessively inherited *TPP2* variations to be linked with the disease, we were interested in how frequently control individuals carry biallelic rare variants. We surveyed our in-house exome database, including more than 10,000 control individuals for *TPP2* variants. Notably, no single individual was found to carry 2 rare *TPP2* variants (MAF \< 2%). These data indicate that rare variants in the *TPP2* gene, particularly when occurring on both alleles, are not well tolerated in healthy individuals.

Because of the close phenotypic resemblance of our family to MS, we wondered whether recessive *TPP2* mutations might also be found in typical MS cases. We sequenced a large MS cohort from Austria, Germany, Canada, and Jordan and identified 1 MS case from Jordan, with a homozygous *TPP2* variant, p.Thr676Ile. However, as this variant also occurs in heterozygous form in other MS cases and in 6 ExAC control individuals, it remains questionable whether this variant is pathogenic.

It was found that TPP2 has a major role in maintaining the cellular homeostasis of amino acids. An increase in lysosomal function and, as a consequence, an inability of immune cells to mobilize aerobic glycolysis was seen in patients with TPP2 LoF mutation.^[@R9]^ Like other cytosolic peptidases, TPP2 influences the MHC Class I metabolism, usually through the destruction of MHC Class I epitopes.^[@R21],[@R22]^ Furthermore, increased MHC Class I and Class II expression has been shown in *TPP2*-deficient mice.^[@R23],[@R24]^ The familial mutation, p.Cys28Gly, results in reduced protein expression in the patients, as seen in the Western blot experiments. However, it does not seem to drastically affect the activity of TPP2 in the patients at least in peripheral blood leukocytes. One can only speculate on possible reasons. TPP2 is a low abundant protein involved in immunologic processes; any circumstances affecting the immune status of a person might also affect protein levels. It might also be that the sensitivity of the enzymatic test is not sufficient to capture small differences. The reduced protein expression in the patients, however, might reflect instability in the complex formed by active TPP2.^[@R18]^ For example, dissociated TPP2 is more sensitive to proteolytic degradation.^[@R25]^

Given the previously reported defect in aerobic glycolysis because of impairment of lysosmal function in TPP2-deficient patients, one could anticipate a similar pathogenic mechanism in our TPP2-mutant patients.^[@R9]^ The aerobic glycolysis pathway is used in situations of high-energy demand. Specifically, tumor cells and immune cells when activated are known to switch their metabolism towards aerobic glycolysis.^[@R26]^ Particularly, induction and suppressive function of regulatory T cells have been shown to be critically dependent on this pathway.^[@R27][@R28][@R30]^ Intriguingly, it was shown that regulatory T cells from relapsing-remitting MS patients have an impaired capacity to induce aerobic glycolysis.^[@R29]^

Our work shows a marked upregulation of TPP2 at sites of active inflammatory demyelination in MS autopsy brain samples without *TPP2* mutations and a reduced TPP2 blood expression in mutation carriers. Why TPP2 is upregulated in MS brains and downregulated in *TPP2* mutation carriers with an MS phenotype cannot be answered here. Is TPP2 upregulation in brain secondary to MS onset and follows as a kind of compensatory mechanism to "defend" the inflammation process? Such a mechanism seems not unreasonable, regarding its role in aerobic glycolysis for immune cell function. This speculation attributes TPP2 a rather protective role in the MS process, which in *TPP2* mutation carriers is no longer fulfilled but instead leads to long-lasting impairment of aerobic glycolysis and consequently to MS.

The pronounced and highly selective expression of TPP2 in cells with high MHC Class I and Class II expression ([figure 2, B](#F2){ref-type="fig"}) suggests an alternative disease mechanism. As mentioned before, TPP2 appears to play a role in peptide trimming and in the destruction of MHC Class I epitopes. Notably, the few known *TPP2* processed epitopes include the Epstein-Barr virus--derived antigen latent membrane protein 1.^[@R31]^ In case of a reduced efficiency or changed specificity of this process because of the TPP2 mutation, one can expect the escape of self-peptides, which may then be recognized by autoreactive T cells in a process that amplifies the inflammatory process.

We argue that the homozygous p.Cys28Gly mutation in the *TPP2* gene is likely responsible for the MS-like phenotype in the present family broadening the phenotypic spectrum of TRIANGLE disease. We therefore consider it as an intriguing possibility that other cases of TPP2-linked brain inflammations might be covered under a diagnosis of MS. The strong increase of TPP2 expression in MS brain lesions in nonmutation carriers suggests a broader role in MS physiopathology. The mechanisms by which *TPP2* mutations contribute to disease pathogenesis cannot be answered in our work. Previous studies claim aerobic glycolysis, lymphocytic immunosenescence, or MHC peptide trimming as candidate mechanisms in disease development. Further functional studies on MS patients with *TPP2* mutations in these particular directions will help to elucidate this question.
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